caa a22 4500 605491038 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0749-4 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0749-4 Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases [Elektronische Daten] [Naoki Izawa, Yusuke Onozawa, Tomomi Hikosaka, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Yutaka Haraguchi, Hirofumi Ogawa, Tetsuo Nishimura, Masahiro Nakagawa, Tomohito Fuke, Yoshiyuki Iida, Tomoyuki Kamijo, Tetsuro Onitsuka, Narikazu Boku, Hirofumi Yasui, Tomoya Yokota] Background: We evaluated the efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) with a high risk of distant metastases compared with CRT alone. Methods: We retrospectively analyzed 29 HNSCC patients with clinical nodal stage N2c, N3, or N2b disease and supraclavicular lymph node metastases receiving CRT alone (CRT group; n=16) or TPF induction chemotherapy followed by CRT (TPF group; n=13) between April 2008 and May 2012. Results: The median follow-up periods were 14.5 (range 5.0-65.0) and 25.0(range 14.0-32.0) months for CRT and TPF groups, respectively. A greater proportion of patient characteristics in the CRT group had advanced T and N stages. The overall response rate to induction TPF was 50.0%; grade 3-4 toxicities included neutropenia, febrile neutropenia, anorexia, and hyponatremia. Complete response rates after CRT completion were 55.5% in the TPF and 42.9% in the CRT group; median overall survival was not reached in the TPF group and was 14.0months in the CRT group (p=0.037). Multivariate analysis revealed that induction TPF and T stage were independent prognostic factors [hazard ratio (HR)=0.196; 95% confidence interval (CI) 0.043-0.898; p=0.036, HR=9.966; 95% CI 2.270-43.75; p=0.002, respectively). Conclusion: TPF followed by CRT is tolerated and may be an option for the treatment of locally advanced stage N2c, N3, or N2b HNSCC. Japan Society of Clinical Oncology, 2014 TPF nationallicence Induction chemotherapy nationallicence Chemoradiotherapy nationallicence Izawa Naoki Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Onozawa Yusuke Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Hikosaka Tomomi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Hamauchi Satoshi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Tsushima Takahiro Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Todaka Akiko Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Machida Nozomu Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Haraguchi Yutaka Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Ogawa Hirofumi Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Nishimura Tetsuo Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Nakagawa Masahiro Division of Plastic and Reconstructive Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Fuke Tomohito Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Iida Yoshiyuki Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Kamijo Tomoyuki Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Onitsuka Tetsuro Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Boku Narikazu Division of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, 216-8511, Kawasaki, Japan aut Yasui Hirofumi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut Yokota Tomoya Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 455-462 1341-9625 20:3<455 2015 20 10147 https://doi.org/10.1007/s10147-014-0749-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0749-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Izawa Naoki Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Onozawa Yusuke Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Hikosaka Tomomi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Hamauchi Satoshi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Tsushima Takahiro Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Todaka Akiko Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Machida Nozomu Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Haraguchi Yutaka Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Ogawa Hirofumi Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Nishimura Tetsuo Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Nakagawa Masahiro Division of Plastic and Reconstructive Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Fuke Tomohito Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Iida Yoshiyuki Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Kamijo Tomoyuki Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Onitsuka Tetsuro Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Boku Narikazu Division of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, 216-8511, Kawasaki, Japan aut NATIONALLICENCE 700 1- Yasui Hirofumi Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 700 1- Yokota Tomoya Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 455-462 1341-9625 20:3<455 2015 20 10147